Skip to content
NBDC Human Database

No datasets in the cart.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0257-v3Release info

Latest

Research title

Development of culturing methods amplifying micro-specimens derived from human pancreas and biliary tract tissues

Research overview

Aims
In this study, we establish organoids using minimal tumor tissue obtained via biopsy or cytology. These organoids are then amplified and cultured to enable various analyses using tumor tissue from individual patients. By comparing the results of these analyses with clinical and pathological factors, we aim to gain insights that will lead to the identification of effective treatments and novel drugs for individual tumors.
Methods
Whole Exome sequencing, RNA sequencing, ATAC sequencing, ChIP sequencing, and Hi-C analysis using organoids established from pancreatic cancer and Intraductal Papillary Mucinous Neoplasm (IPMN).
Long read RNA-seq analysis using organoids established from pancreatic cancer, IPMN, IPMN-derived pancreatic cancers and Non-tumor pancreatic tissue.
Participants/materials
Pancreatic ductal adenocarcinoma, IPMN, Pancreatic cancer, IPMN-derived pancreatic cancers , Non-tumor pancreatic tissue
URL
N/A

Datasets

CartDataset IDType of dataPlatformsAccess criteriaDate published
JGAD000366NGS (Exome, RNA-seq)
  • Illumina HiSeq 2500
  • Illumina NovaSeq 6000
Controlled-access (Type I)2021-12-27
E-GEAD-414NGS (RNA-seq)
  • Illumina HiSeq 2500
  • Illumina NovaSeq 6000
Unrestricted-access2021-12-27
JGAD000367NGS (ATAC-seq, ChIP-seq)
  • Illumina NextSeq 500
Controlled-access (Type I)2021-12-24
E-GEAD-416NGS (ATAC-seq)
  • Illumina NextSeq 500
Unrestricted-access2021-12-27
E-GEAD-417NGS (ChIP-seq)
  • Illumina NextSeq 500
Unrestricted-access2021-12-27
JGAD000365NGS (Hi-C)
  • Illumina NovaSeq 6000
Controlled-access (Type I)2021-12-24
E-GEAD-415NGS (Hi-C)
  • Illumina NovaSeq 6000
Unrestricted-access2021-12-27
JGAD000633NGS (RNA-seq, ChIP-seq, Hi-C)
  • Illumina HiSeq 2500
  • Illumina NextSeq 500
  • Illumina NovaSeq 6000
Controlled-access (Type I)2023-01-05
JGAD001103NGS (RNA-seq)
  • Oxford Nanopore Technologies MinION
Controlled-access (Type I)2026-11-05

Data provider

Principal investigator
Keisuke Tateishi
Affiliation
Department of Gastroenterology, The University of Tokyo

Research projects

No research projects.

Grants

NameTitleProject number
KAKENHI Grant-in-Aid for Scientific Research (C)
Comprehensive biological network analysis of pancreatic cancer
  • 19K08435
KAKENHI Grant-in-Aid for Scientific Research (C)
Stratification and optimization of pancreatic cancer treatment based on chromatin dynamics
  • 21K15966

Related publications

TitleDOIDataset ID
MNX1-HNF1B axis is indispensable for intraductal papillary mucinous neoplasm lineages
HNF1B-driven three-dimensional chromatin structure for molecular classification in pancreatic cancers

Controlled access users

Principal investigatorAffiliationCountry/RegionResearch titlePeriod of data useDataset ID
Michiaki HamadaHamada Laboratory, Faculty of Science and Engineering, Waseda UniversityJapanConstruction of RNA-targeted Drug Discovery Database2023-01-05 – 2027-10-31
Takuya YamamotoCenter for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and NutritionJapanBasic research for vaccine development against gastrointestinal cancer and malignant melanoma based on the identification of novel cancer antigens 2024-11-12 – 2027-03-31